Maximum quantity allowed is 999
请选择数量
CAS RN: 84611-23-4 | 產品號碼: E1026
| 產品號碼 | E1026 |
純度/分析方法 
|
>98.0%(GC)(T) |
| 分子式 / 分子量 | C__8H__1__1NO__4S__2 = 249.30 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| 包裝和容器
|
1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 84611-23-4 |
| Reaxys-RN | 6972806 |
| PubChem Substance ID | 253661978 |
| Merck Index(14) | 3647 |
| MDL編號 | MFCD00867664 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 160.0 to 164.0 °C |
性質
| 熔點 | 162 °C |
| Maximum Wavelength | 236 nm (H__2O) |
GHS
相關法規
| RTECS # | AJ1476200 |
運輸資料
| HS編碼* | 2934.99-000 |
Application
Erdosteine: A Unique Prodrug with a Multifactorial Mechanism of Action
Erdosteine is an inactive prodrug with a multifactorial mechanism of action, namely: mucolytic, antibacterial, antioxidant and anti-inflammatory activity. Following first-pass metabolism, the opening of the thiolactone ring and deacetylation of the aliphatic side chain, the methabolite is the active metabolite of erdosteine owing to its free thiol group. Erdosteine is currently used for treatment of chronic obstructive pulmonary disease (COPD). (The product is for research purpose only.)
References
- Erdosteine (a review)
- Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts
- Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats
- Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats
- An overview of erdosteine antioxidant activity in experimental research (a review)
- Erdosteine: antitussive and anti-inflammatory effects (a review)
考研文獻
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。